SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
European EV Sales Surge in April 2026 as Tesla and Chinese Automakers Gain Ground 
DOJ Investigates Group Linked to Reid Hoffman Over E. Jean Carroll Lawsuit Funding 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge 
Elon Musk Explores Possible Tesla-SpaceX Merger Amid Growing AI Investments 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Nvidia and Microsoft to Launch AI-Powered Windows PCs at Computex 2026 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
US Quantum Stocks Surge After $2 Billion Government Investment 
Lunit, a deep learning-based medical AI company based in South Korea, moved closer to acquiring Volpara Health Technologies Ltd. after the high court in New Zealand issued first-phase approval for the deal.
Lunit is trying to buy Volpara Health, which specializes in making software to save people from cancer. To fulfill its mission of conquering the deadly disease through modern technology, Lunit needs to secure approval from regulators in NZ since the latter is headquartered in the region.
Moving Forward With the Buyout Deal
According to The Korea Economic Daily, the Lunit and Volpara Health agreement is finally moving forward after the high court gave its "go-ahead" for the deal to proceed. With how things are progressing, it was reported that the companies may finalize their acquisition contract by May.
On Thursday, May 14, the South Korean medical AI firm announced it had secured the first approval from the High Court of New Zealand for its plan to buy the NZ-based AI breast cancer diagnostics solutions company.
Moreover, Lunit shared that the acquisition process required by the local court in the region consists of key steps. The first is obtaining the shareholders' approval and the sale vote, and the second is assessing the validity and effectiveness of the meeting's outcome. It was noted that Volpara scheduled a shareholders' meeting for April 12.
Lunit in the American Market
Meanwhile, Lunit's acquisition of Volpara will position the company as a dominant force in the U.S. market for mammography solutions. Once merged, the companies will also improve related artificial intelligence solutions while laying out the foundation for the development of autonomous AI models in the future.
"We are pleased to announce the High Court's approval, a significant step in our remarkable journey. As we approach the final stage where Volpara's shareholders will cast their votes, I would also like to share that our funding for this acquisition is progressing seamlessly, ensuring everything is on track," Lunit's chief executive officer, Brandon Suh, said in a press release. "We are confident that the synergies between Lunit and Volpara will create a powerful force in advancing AI-driven solutions for the benefit of cancer care professionals and patients worldwide."
Photo by: Lunit Press Release
